论文部分内容阅读
目的探讨乳腺癌扩增性抗原1(AIB1)及增殖细胞核抗原(Ki67)蛋白在乳腺浸润性导管癌(IDC)中的表达及二者相关性。方法采用免疫组织化学SP法检测100例乳腺IDC组织石蜡标本中AIB1及Ki67蛋白的表达情况。结果 AIB1及Ki67蛋白阳性表达率分别为75.00%和80.00%。它们的表达均与腋窝淋巴结转移、病理组织学分级、临床分期关系密切(P<0.05),而均与患者年龄无关(P>0.05);AIB1表达与肿瘤大小无关(P>0.05),而Ki67表达与肿瘤大小有关(P<0.05);多因素Logistic回归分析显示,组织学分级是影响AIB1及Ki67阳性表达最主要因素,P值均<0.05;在80例Ki67蛋白阳性表达的乳腺IDC中有68例同时表达AIB1,AIB1与Ki67的表达呈正相关(P<0.05)。结论 AIB1及Ki67蛋白可能是乳腺IDC患者的不良预后因素;二者可能共同促进乳腺癌细胞增殖、侵袭及转移,联合检测可能有助于更准确地判断乳腺IDC的预后。
Objective To investigate the expression of AIB1 and Ki67 in breast invasive ductal carcinoma (IDC) and their relationship. Methods Immunohistochemical SP method was used to detect the expression of AIB1 and Ki67 in 100 cases of breast IDC tissues. Results The positive rates of AIB1 and Ki67 protein were 75.00% and 80.00%, respectively. The expression of AIB1 was not associated with the size of the tumor (P> 0.05), but the expression of Ki67 was significantly correlated with the lymph node metastasis, histopathological grade and clinical stage (P <0.05) (P <0.05). Multivariate Logistic regression analysis showed that histological grade was the most important factor affecting the expression of AIB1 and Ki67, both P <0.05. Among the 80 cases of IDC with positive Ki67 expression 68 cases of simultaneous expression of AIB1, AIB1 and Ki67 expression was positively correlated (P <0.05). Conclusions AIB1 and Ki67 proteins may be unfavorable prognostic factors in breast IDC patients. Both of them may jointly promote the proliferation, invasion and metastasis of breast cancer cells. Combined detection may help to determine the prognosis of breast IDC more accurately.